Terms: = Ovarian cancer AND ACSL3, PRO2194, 2181, ENSG00000123983, O95573, FACL3, ACS3 AND Prognosis
2 results:
1. The use of bevacizumab is correlated with improved post-progression survival in advanced recurrent ovarian cancer.
Yanazume S; Ushiwaka T; Fukuda M; Togami S; Kamio M; Kobayashi H
Jpn J Clin Oncol; 2021 Aug; 51(9):1407-1415. PubMed ID: 34240168
[TBL] [Abstract] [Full Text] [Related]
2. Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in cancer.
Chen WC; Wang CY; Hung YH; Weng TY; Yen MC; Lai MD
PLoS One; 2016; 11(5):e0155660. PubMed ID: 27171439
[TBL] [Abstract] [Full Text] [Related]
